Shares of ADMA Biologics Inc. (ADMA) have surged over the past year, driven by increased sales of its immunoglobulin products, a strategic advantage with no tariff-related challenges, and a promising regulatory update that enhances production capabilities and accelerates pipeline development.
This commercial-stage company develops specialty plasma-derived products for the prevention and treatment of infectious diseases in immunocompromised and other patients at risk for infection.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.